Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/26/2024 | $3.00 | Buy | Maxim Group |
| 7/3/2024 | $4.00 | Buy | H.C. Wainwright |
| 11/7/2022 | $7.00 | Buy | Lake Street |
LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners Healthcare Company Showcase, taking place Wednesday, May 21, 2025. Mr. O'Grady's fireside chat will be webcast live at 11:20 a.m. ET. To join the event, please register at https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw#/registration, or visit the Events & Presentations page at the Company's investor relations website, https://investor.assertiotx.com/. About Assertio Assertio is a pharmaceutical company with comprehensive commercial cap
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, investors participating in the conference can request 1x1 meetings to take place on March 26, 2025 via their conference representative or through Assertio investor relations at [email protected]. T
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b
LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
S-8 - Assertio Holdings, Inc. (0001808665) (Filer)
8-K - Assertio Holdings, Inc. (0001808665) (Filer)
10-Q - Assertio Holdings, Inc. (0001808665) (Filer)
Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00
H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00
Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
4 - Assertio Holdings, Inc. (0001808665) (Issuer)
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Brendan O'Grady, Chief Executive Officer, "In line with our strategy for Assertio's long-term growth, 2024 was a year of stabilization as we transitioned to Rolvedon as our primary a
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for a